Clinical-stage biotech Cara Therapeutics (NASDAQ: CARA) reports earnings on March 9, but investors won't be paying much attention to the financials. With important information on clinical trials of ...

Stamford-based Cara Therapeutics Inc. announced Monday that its board of directors has approved a 1-for-3 reverse common stock stock split. Cara’s common stock, which trades on the Nasdaq stock ...

Newly public Tvardi Therapeutics, Inc. (NASDAQ:TVRD) is capturing investor attention following its recent reverse merger with Cara Therapeutics, Inc. In April, the company completed its previously ...

STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA Former Attorney General of Louisiana Charles ...

Tvardi anticipates reporting topline data from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis (IPF), in the second ...

Two shareholders have filed separate lawsuits in New York seeking to block the proposed merger of Stamford-based Cara Therapeutics Inc. with Houston-based Tvardi Therapeutics Inc. Cara and Tvardi ...

STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...

Cara Therapeutics (CARA) announced that its board has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara’s common stock is expected to begin trading on a reverse ...

STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. (the “Company”), today announced that its Board of Directors (the “Board”) has approved a 1-for-3 reverse stock split ...